"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Descriptor ID |
D020714
|
MeSH Number(s) |
E05.940.481 G07.690.936.625
|
Concept/Terms |
Maximum Tolerated Dose- Maximum Tolerated Dose
- Dose, Maximum Tolerated
- Doses, Maximum Tolerated
- Maximum Tolerated Doses
- Tolerated Dose, Maximum
- Tolerated Doses, Maximum
- Maximally Tolerated Dose
- Dose, Maximally Tolerated
- Doses, Maximally Tolerated
- Maximally Tolerated Doses
- Tolerated Dose, Maximally
- Tolerated Doses, Maximally
- Maximal Tolerated Dose
- Dose, Maximal Tolerated
- Doses, Maximal Tolerated
- Maximal Tolerated Doses
- Tolerated Dose, Maximal
- Tolerated Doses, Maximal
|
Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".
Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".
This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in this website by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 1 | 15 | 16 |
2018 | 0 | 12 | 12 |
2019 | 0 | 7 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.
-
Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine. 2021 Jul; 87:153591.
-
Early phase dose-finding trials in virology. Stat Med. 2021 01 30; 40(2):240-253.
-
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clin Cancer Res. 2019 12 15; 25(24):7351-7362.
-
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. Lung Cancer. 2019 11; 137:136-143.
-
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs. 2020 06; 38(3):831-843.
-
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 08; 20(8):1160-1170.
-
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. J Thorac Oncol. 2019 10; 14(10):1794-1806.
-
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019 03; 109:103-110.
-
A study on factors determining dose of topical lignocaine during broncho-alveolar lavage by spray-as-you-go technique: A single centre observational study. Drug Discov Ther. 2019; 13(2):89-95.
-
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 12 18; 138(25):2884-2894.